Randomized, double-blind, placebo-controlled, parallel-group, multi-center study of the safety and efficacy of ADAM zolmitriptan for the acute treatment of migraine

por Spierings, Egilius LH, Brandes, Jan Lewis, Kudrow, David B, Weintraub, James, Schmidt, Peter C, Kellerman, Donald J, Tepper, Stewart J
Publicado 2017